- Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension.Laffin LJ, et al; Advance-HTN Investigators. N Engl J Med. 2025 May 8;392(18):1813-1823.Pour en savoir plus : Lire
- Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.Desai AS, et al; KARDIA-2 Study Group. JAMA. 2025 May 28:e256681. Pour en savoir plus : Lire
- Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study.He Y, et al. Circulation. 2025 May 27;151(21):1544-1546. Lire
- Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial. Lee CJ, et al. JAMA. 2025 May 14:e255129. Pour en savoir plus : Lire
- Establishing Reference Values for Pulse Wave Velocity in Young People.Kodithuwakku V, et al; Youth Vascular Consortium collaborators. Hypertension. 2025 May 14. doi: 10.1161/HYPERTENSIONAHA. Pour en savoir plus: Lire
- Heat extremes and cardiovascular Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, European Heart Rhythm Association of the ESC, the ESC Council on Hypertension, the ESC Council on Stroke, and the ESC Working Group on Cardiovascular Pharmacotherapy.Chaseling GK, et al. Eur Heart J. 2025 Jun 3:ehaf326. Pour en savoir plus Lire
- Priorities for Research on Hypertension Care Delivery: A WHO Report Executive Summary. Matsushita K, et al. Hypertension. 2025 Jun;82(6):971-976. doi: 10.1161/HYPERTENSIONAHA.125.24702. PMID: 40109247 Pour en savoir plus : Lire